View Filing Data

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2019
Document And Entity Information
Entity Registrant Name	BioLineRx Ltd.
Entity Central Index Key	0001498403
Document Type	6-K
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (UNAUDITED) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash and cash equivalents	$ 4,972	$ 3,404
Short-term bank deposits	30,256	26,747
Prepaid expenses	451	488
Other receivables	528	1,339
Total current assets	36,207	31,978
NON-CURRENT ASSETS
Long-term prepaid expenses	60	56
Property and equipment, net	2,047	2,227
Right-of-use assets	1,716
Intangible assets, net	21,928	21,972
Total non-current assets	25,751	24,255
Total assets	61,958	56,233
CURRENT LIABILITIES
Current maturities of long-term loans	2,395	895
Accounts payable and accruals:
Trade	4,565	4,493
Other	927	1,363
Lease liabilities	672
Total current liabilities	8,559	6,751
NON-CURRENT LIABILITIES
Warrants	3,938	323
Long-term loans, net of current maturities	6,583	7,838
Lease liabilities	1,096
Total non-current liabilities	11,617	8,161
COMMITMENTS AND CONTINGENT LIABILITIES
Total liabilities	20,176	14,912
EQUITY
Ordinary shares	4,001	3,110
Share premium	261,522	250,192
Capital reserve	11,835	11,955
Other comprehensive loss	(1,416)	(1,416)
Accumulated deficit	(234,160)	(222,520)
Total equity	41,782	41,321
Total liabilities and equity	$ 61,958	$ 56,233

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Profit or loss [abstract]
RESEARCH AND DEVELOPMENT EXPENSES	$ (5,302)	$ (4,484)	$ (9,694)	$ (9,554)
SALES AND MARKETING EXPENSES	(226)	(360)	(482)	(844)
GENERAL AND ADMINISTRATIVE EXPENSES	(949)	(883)	(1,879)	(1,958)
OPERATING LOSS	(6,477)	(5,727)	(12,055)	(12,356)
NON-OPERATING INCOME, NET	1,261	663	921	1,125
FINANCIAL INCOME	171	287	381	462
FINANCIAL EXPENSES	(440)	(11)	(887)	(217)
NET LOSS AND COMPREHENSIVE LOSS	$ (5,485)	$ (4,788)	$ (11,640)	$ (10,986)
LOSS PER ORDINARY SHARE - BASIC AND DILUTED	$ (0.04)	$ (0.05)	$ (0.08)	$ (0.1)
WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF LOSS PER ORDINARY SHARE	145,461,598	106,630,704	139,270,178	106,524,332

CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) - USD ($) $ in Thousands	Ordinary shares [Member]	Share premium [Member]	Capital reserve [Member]	Other comprehensive loss [Member]	Accumulated deficit [Member]	Total
BALANCE at Dec. 31, 2017	$ 2,836	$ 240,682	$ 10,337	$ (1,416)	$ (199,558)	$ 52,881
CHANGES FOR
Issuance of share capital, net	83	2,764				2,847
Employee stock options exercised	1	38	(39)
Employee stock options forfeited and expired		399	(399)
Share-based compensation			1,444			1,444
Comprehensive loss for the period					(10,986)	(10,986)
BALANCE at Jun. 30, 2018	2,920	243,883	11,343	(1,416)	(210,544)	46,186
BALANCE at Dec. 31, 2018	3,110	250,192	11,955	(1,416)	(222,520)	41,321
CHANGES FOR
Issuance of share capital, net	890	10,437				11,327
Employee stock options exercised	1	27	(27)			1
Employee stock options forfeited and expired		866	(866)
Share-based compensation			773			773
Comprehensive loss for the period					(11,640)	(11,640)
BALANCE at Jun. 30, 2019	$ 4,001	$ 261,522	$ 11,835	$ (1,416)	$ (234,160)	$ 41,782

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2018-01-01
-Paragraph 18
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=7&date=2018-03-01&anchor=para_18_b&doctype=Standard
-URIDate 2018-03-16

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2018-01-01
-Paragraph 24
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=1&date=2018-03-01&anchor=para_24_b&doctype=Standard
-URIDate 2018-03-16

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2018-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=1&date=2018-03-01&anchor=para_32_a_ii&doctype=Standard
-URIDate 2018-03-16

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2018-01-01
-Paragraph 28
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=8&date=2018-03-01&anchor=para_28_b&doctype=Standard
-URIDate 2018-03-16

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2018-01-01
-Paragraph 39L
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=4&date=2018-03-02&anchor=para_39L_e&doctype=Standard&book=b
-URIDate 2018-03-16

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2018-01-01
-Paragraph 23
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=8&date=2018-03-01&anchor=para_23&doctype=Standard
-URIDate 2018-03-16

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2018-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=12&date=2018-03-01&anchor=para_B10_b&doctype=Appendix&seq=2
-URIDate 2018-03-16

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2018-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2018-03-01&anchor=para_106_d_i&doctype=Standard
-URIDate 2018-03-16

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2021-01-01
-Name IFRS
-Number 17
-IssueDate 2018-01-01
-Paragraph 113
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=17&date=2018-03-01&anchor=para_113_b&doctype=Standard
-URIDate 2018-03-16

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2018-01-01
-Paragraph 81A
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2018-03-01&anchor=para_81A_a&doctype=Standard
-URIDate 2018-03-16

+ Details

CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS (UNAUDITED) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
CASH FLOWS - OPERATING ACTIVITIES
Comprehensive loss for the period	$ (11,640)	$ (10,986)
Adjustments required to reflect net cash used in operating activities (see appendix below)	573	(2,054)
Net cash used in operating activities	(11,067)	(13,040)
CASH FLOWS - INVESTING ACTIVITIES
Investments in short-term deposits	(27,510)	(15,000)
Maturities of short-term deposits	24,441	24,385
Proceeds from realization of long-term investment		1,500
Purchase of property and equipment	(53)	(76)
Purchase of intangible assets		(37)
Net cash provided by (used in) investing activities	(3,122)	10,772
CASH FLOWS - FINANCING ACTIVITIES
Issuances of share capital and warrants, net of issuance cost	15,879	2,847
Employee stock options exercised	1
Repayments of loans	(47)	(47)
Repayments of lease liabilities	(110)
Net cash provided by financing activities	15,723	2,800
INCREASE IN CASH AND CASH EQUIVALENTS	1,534	532
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD	3,404	5,110
EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS	34	147
CASH AND CASH EQUIVALENTS - END OF PERIOD	4,972	5,789
Income and expenses not involving cash flows:
Depreciation and amortization	439	288
Long-term prepaid expenses	(4)	(2)
Exchange differences on cash and cash equivalents	(34)	(147)
Gain on adjustment of warrants to fair value	(1,354)	(625)
Gain on realization of long-term investment		(500)
Share-based compensation	773	1,444
Warrant issuance costs	417
Interest and exchange rate differences on short-term deposits	(440)	(351)
Interest on loans	292	(1)
Total income and expense not involving cash flows	89	106
Changes in operating asset and liability items:
Decrease (increase) in prepaid expenses and other receivables	848	(776)
Decrease in accounts payable and accruals	(364)	(1,384)
Total Change in operating asset and liability	484	(2,160)
Total Adjustments required to reflect net cash used in operating acivities	573	(2,054)
Supplemental information on interest received in cash	442	377
Supplemental information on interest paid in cash	477	167
Supplemental information on non-cash transaction:
Initial establishment of right-of-use assets against lease liabilities	$ 1,878

GENERAL INFORMATION

6 Months Ended

Jun. 30, 2019

Disclosure of general information [Abstract]

GENERAL INFORMATION

NOTE 1 – GENERAL INFORMATION

General

BioLineRx Ltd. (“BioLineRx”), headquartered in Modi’in, Israel, was incorporated and commenced operations in April 2003.

BioLineRx and its subsidiaries (collectively, the “Company”) are engaged in the development of therapeutics, primarily in clinical-stages, with a focus on the field of oncology.

In February 2007, BioLineRx listed its ordinary shares on the Tel Aviv Stock Exchange (“TASE”) and they have been traded on the TASE since that time. Since July 2011, BioLineRx’s American Depositary Shares (“ADSs”) have also been traded on the NASDAQ Capital Market.

In March 2017, the Company acquired Agalimmune Ltd. (“Agalimmune”), a privately-held company incorporated in the United Kingdom, with a focus on the field of immuno-oncology.

Although the Company has generated significant revenues from a number of out-licensing transactions in the past, the Company cannot determine with reasonable certainty when and if it will have sustainable profits.

Approval of financial statements

The condensed consolidated interim financial statements of the Company as of June 30, 2019, and for the three and six months then ended, were approved by the Board of Directors on August 6, 2019, and signed on its behalf by the Chairman of the Board, the Chief Executive Officer and the Chief Financial Officer.

BASIS OF PREPARATION	6 Months Ended
BASIS OF PREPARATION	Jun. 30, 2019
Disclosure of basis of preparation [Abstract]
BASIS OF PREPARATION	NOTE 2 – BASIS OF PREPARATION The Company’s condensed consolidated interim financial statements as of June 30, 2019 and for the three and six months then ended (the “interim financial statements”) have been prepared in accordance with International Accounting Standard No. 34, “Interim Financial Reporting” (“IAS 34”). These interim financial statements, which are unaudited, do not include all disclosures necessary for a fair statement of financial position, results of operations, and cash flows in conformity with International Financial Reporting Standards (“IFRS”). The condensed consolidated interim financial statements should be read in conjunction with the Company’s annual financial statements as of December 31, 2018 and for the year then ended and their accompanying notes, which have been prepared in accordance with IFRS. The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the entire fiscal year or for any other interim period.

SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2019

Disclosure of significant accounting policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES

The accounting policies and calculation methods applied in the preparation of these interim financial statements are consistent with those applied in the preparation of the annual financial statements as of December 31, 2018 and for the year then ended, except for the adoption of IFRS No. 16, “Leases”.

Adjustments recognized on adoption of IFRS 16

The Company has adopted IFRS 16 retrospectively from January 1, 2019 but has not restated comparatives for the 2018 reporting period, as permitted under the specific transitional provisions in the standard. On adoption of IFRS 16, the Company recognized lease liabilities in relation to leases which had previously been classified as “operating leases” under the principles of IAS 17, “Leases.” These liabilities were measured at the present value of the remaining lease payments, discounted using the lessee’s incremental borrowing rate as of January 1, 2019. The remeasurements to the lease liabilities were recognized as adjustments to the related right-of-use assets immediately after the date of initial application. The associated right-of-use assets for property leases were measured on a retrospective basis as if the new rules had always been applied. Other right-of use assets were measured at the amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments relating to that lease recognized in the balance sheet as of December 31, 2018. The lessee’s weighted average incremental borrowing rate applied to the lease liabilities on January 1, 2019 was 15.1%.

	January 1,		June 30,
	2019		2019
Composition of right-of-use assets by type:
Property		1,552		1,485
Motor vehicles		326		231
Total right-of-use asset		1,878		1,716

Composition of lease liabilities recognized as of January 1, 2019:
Current lease liabilities			713
Non-current lease liabilities			1,165
			1,878

Practical expedients applied on adoption of IFRS 16

In applying IFRS 16 for the first time, the Company has used the following practical expedients permitted by the standard:

•

Use of a single discount rate to a portfolio of leases with reasonably similar characteristics;

•

Reliance on previous assessments on whether leases are onerous;

•

Accounting for operating leases with a remaining lease term of less than 12 months as of January 1, 2019, as short-term leases;

•

Exclusion of initial direct costs for the measurement of the right-of-use asset at the date of initial application;

•

Use of hindsight in determining the lease term where the contract contains options to extend or terminate the lease.

The Company has also elected not to reassess whether a contract is, or contains, a lease at the date of initial application. Instead, for contracts entered into before the transition date, the Company relied on its assessment made applying IAS 17 and IFRIC 4, “Determining whether an Arrangement contains a Lease.”

Other information relating to IFRS 16

As of June 30, 2019, the weighted average remaining lease term on the Company’s existing leases was 11.0 years for its property lease and 1.2 years for motor vehicle leases. Lease expense (substantially all of which is non-cash) for the six months ended June 30, 2019 amounted to $0.2 million. Cash paid for amounts included in the measurement of the operating lease liabilities for the six months ended June 30, 2019 was $0.1 million.

ISSUANCES OF SHARE CAPITAL AND WARRANTS

6 Months Ended

Jun. 30, 2019

Disclosure of issuances of share capital and warrants [Abstract]

ISSUANCES OF SHARE CAPITAL AND WARRANTS

NOTE 4 – ISSUANCES OF SHARE CAPITAL AND WARRANTS

At-the-market (“ATM”) sales agreement with BTIG

In October 2017, the Company entered into an at-the-market (“ATM”) sales agreement with BTIG, LLC (“BTIG”), pursuant to which the Company may, at its sole discretion, offer and sell through BTIG, acting as sales agent, ADSs having an aggregate offering price of up to $30.0 million throughout the period during which the ATM facility remains in effect. The Company will pay BTIG a commission of 3.0% of the gross proceeds from the sale of ADSs under the facility. From the effective date of the agreement through June 30, 2019, 9,655,387 ADSs were sold under the program for total net proceeds of approximately $7.0 million, leaving an available balance under the facility of approximately $23.0 million as of June 30, 2019.

Underwritten public offering

In February 2019, the Company completed an underwritten public offering of 28,000,000 of its ADSs and warrants to purchase 28,000,000 ADSs, at a public offering price of $0.55 per ADS and accompanying warrant. The warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $0.75 per ADS. The offering raised a total of $15.4 million, with net proceeds of $14.1 million, after deducting fees and expenses. The amount of the offering consideration initially allocated to the warrants was $5.0 million. Total issuance costs initially allocated to the warrants were $0.4 million.

The warrants issued have been classified as a non-current financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the date the contract was entered into and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss.

The fair value of the warrants is computed using the Black and Scholes option pricing model. The fair value of the warrants upon issuance was computed based on the then current price of an ADS, a risk-free interest rate of 2.50% and an average standard deviation of 62.8%. The fair value of the warrants as of June 30, 2019 was based on the then current price of an ADS, a risk-free interest rate of 1.76% and an average standard deviation of 65.2%. The change in fair value from the date of issuance through June 30, 2019 amounted to $1.3 million.

SHAREHOLDERS' EQUITY

6 Months Ended

Jun. 30, 2019

Disclosure of classes of share capital [abstract]

SHAREHOLDERS' EQUITY

NOTE 5 – SHAREHOLDERS’ EQUITY

As of December 31, 2018 and June 30, 2019, share capital is composed of ordinary shares, as follows:

	Number of ordinary shares
	December 31,		June 30,
	2018		2019

Authorized share capital		250,000,000		250,000,000

Issued and paid-up share capital		114,933,144		147,183,744

	In USD and NIS
	December 31,		June 30,
	2018		2019

Authorized share capital (in NIS)		25,000,000		25,000,000

Issued and paid-up share capital (in NIS)		11,493,314		14,718,374

Issued and paid-up share capital (in USD)		3,109,746		4,000,676

EVENT SUBSEQUENT TO THE BALANCE SHEET DATE	6 Months Ended
EVENT SUBSEQUENT TO THE BALANCE SHEET DATE	Jun. 30, 2019
Disclosure of non-adjusting events after reporting period [abstract]
EVENT SUBSEQUENT TO THE BALANCE SHEET DATE	NOTE 6 – EVENT SUBSEQUENT TO THE BALANCE SHEET DATE On July 15, 2019, the Company implemented a change in the ratio of its ADSs to ordinary shares, from one ADS representing one ordinary share to a new ratio of one ADS representing 15 ordinary shares.

SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2019

Disclosure of significant accounting policies [Abstract]

Schedule of Composition of Right-of-Use Assets

	January 1,		June 30,
	2019		2019
Composition of right-of-use assets by type:
Property		1,552		1,485
Motor vehicles		326		231
Total right-of-use asset		1,878		1,716

Composition of lease liabilities recognized as of January 1, 2019:
Current lease liabilities			713
Non-current lease liabilities			1,165
			1,878

SHAREHOLDERS' EQUITY (Tables)

6 Months Ended

Jun. 30, 2019

Disclosure of classes of share capital [abstract]

Schedule of Share Capital

As of December 31, 2018 and June 30, 2019, share capital is composed of ordinary shares, as follows:

	Number of ordinary shares
	December 31,		June 30,
	2018		2019

Authorized share capital		250,000,000		250,000,000

Issued and paid-up share capital		114,933,144		147,183,744

	In USD and NIS
	December 31,		June 30,
	2018		2019

Authorized share capital (in NIS)		25,000,000		25,000,000

Issued and paid-up share capital (in NIS)		11,493,314		14,718,374

Issued and paid-up share capital (in USD)		3,109,746		4,000,676

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jan. 02, 2019
Disclosure of detailed information about property, plant and equipment [line items]
Weighted average incremental borrowing rate of lease liabilities		15.10%
Lease expense	$ 200
Cash paid for amounts included in the measurement of the operating lease liabilities	$ 100
Property [member]
Disclosure of detailed information about property, plant and equipment [line items]
Weighted Average Remaining Lease Term	11 years
Motor vehicles [member]
Disclosure of detailed information about property, plant and equipment [line items]
Weighted Average Remaining Lease Term	1 year 2 months 12 days

SIGNIFICANT ACCOUNTING POLICIES (Schedule of Composition of Right-of-Use Assets) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 02, 2019
Disclosure of significant accounting policies [Abstract]
Property	$ 1,485	$ 1,552
Motor vehicles	231	326
Total right-of-use asset	$ 1,716	$ 1,878

SIGNIFICANT ACCOUNTING POLICIES (Schedule of Composition of Lease Liabilities Recognized) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 02, 2019
Disclosure of significant accounting policies [Abstract]
Current lease liabilities	$ 672	$ 713
Non-current lease liabilities	$ 1,096	1,165
Total Lease Liabilities		$ 1,878

ISSUANCES OF SHARE CAPITAL AND WARRANTS (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended
	Feb. 28, 2019	Jun. 30, 2019	Jun. 30, 2018	Oct. 31, 2017
Disclosure of terms and conditions of share-based payment arrangement [line items]
Proceeds from shares issued		$ 15,879	$ 2,847
Change in fair value of issuance		$ 1,300
ADS [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk-free interest rate	2.50%	1.76%
Average standard deviation	62.80%	65.20%
BTIG, LLC [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Aggregate offering price				$ 30,000
Percentage of commission on sales agreement				3.00%
Share purchase agreement, shares		9,655,387
Available balance under the facility		$ 23,000
Proceeds from shares issued		$ 7,000
Public offering [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of shares issued	28,000,000
Number of warrant purchase	28,000,000
Offering price per ADS	$ 0.55
Expiry	Five years
Exercise of price per ADS	$ 0.75
Proceeds from shares issued	$ 15,400
Net proceeds from shares issued after deducting fees and expenses	14,100
Public offering [Member] \| Warrant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Proceeds from shares issued	5,000
Issuance costs	$ 400

SHAREHOLDERS' EQUITY (Schedule of Share Capital) (Details) ₪ in Thousands, $ in Thousands	Jun. 30, 2019 USD ($) shares	Jun. 30, 2019 ILS (₪) shares	Dec. 31, 2018 USD ($) shares	Dec. 31, 2018 ILS (₪) shares
Number of Ordinary Shares
Authorized share capital \| shares	250,000,000	250,000,000	250,000,000	250,000,000
Issued and paid-up share capital \| shares	147,183,744	147,183,744	114,933,144	114,933,144
Issued and paid-up share capital \| $	$ 4,000,676		$ 3,109,746
NIS [Member]
Number of Ordinary Shares
Authorized share capital \| ₪		₪ 25,000,000		₪ 25,000,000
Issued and paid-up share capital \| ₪		₪ 14,718,374		₪ 11,493,314